1. Home
  2. Directory
  3. Massachusetts
  4. Stoneham
  5. Otolaryngology
  6. NPI Profile
  7. Prescriptions 1265467310

DUKHEE RHEE M.D.
Prescription History 1265467310
Otolaryngology in Stoneham, MA

NPI Status: Active since July 11, 2006

Contact Information

41 MONTVALE AVE STE 200
STONEHAM, MA
ZIP 02180
Phone: (781) 279-0971

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DUKHEE RHEE M.D., an active Otolaryngology specialist practicing in Stoneham, MA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 120 documented patient claims. Among these therapy options, the most frequently utilized medication is Fluticasone Propionate, which accounts for 37 claims alone.

Medication Index

Azelastine Hcl

Generic Formulation: Azelastine HclSpecialty: Otolaryngology
Provider Metrics Summary
Total Claims 15
30-Day Fills 20.0
Days Supply 545
MA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills54.6
Peer Average Days Supply1,598
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.1% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $710.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$47.33

State Avg Cost Per Claim

$50.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. Azelastine belongs to a class of drugs known as antihistamines. It works by blocking certain natural substances called histamines that are responsible for nasal symptoms.

Fluocinolone Acetonide Oil

Generic Formulation: Fluocinolone Acetonide OilSpecialty: Otolaryngology
Provider Metrics Summary
Total Claims 28
30-Day Fills 30.0
Days Supply 645
MA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills29.8
Peer Average Days Supply717
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,087.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.85

State Avg Cost Per Claim

$65.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat eczema of the outer ear (also known as chronic itchy ear). The main symptom is itchiness, but redness, flaking, or oozing may also occur. Fluocinolone reduces these symptoms. This medication is a low- to medium-strength corticosteroid.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Otolaryngology
Provider Metrics Summary
Total Claims 37
30-Day Fills 71.0
Days Supply 2,130
MA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills83.6
Peer Average Days Supply2,498
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $478.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.93

State Avg Cost Per Claim

$18.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Ipratropium Bromide

Generic Formulation: Ipratropium BromideSpecialty: Otolaryngology
Provider Metrics Summary
Total Claims 18
30-Day Fills 32.9
Days Supply 931
MA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills51.2
Peer Average Days Supply1,430
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $400.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.24

State Avg Cost Per Claim

$48.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Ofloxacin

Generic Formulation: OfloxacinSpecialty: Otolaryngology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 270
MA State Average Benchmarks
Peer Average Claims84.0
Peer Average 30-Day Fills88.4
Peer Average Days Supply1,820
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.8% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $869.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.52

State Avg Cost Per Claim

$16.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.

Therapeutic Applications

This medication is used to treat eye infections. Ofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DUKHEE RHEE M.D. provides transparency into local medical care patterns within Stoneham, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Otolaryngology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.